Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003357 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00003357: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003357 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003357, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients with breast cancer who have no evidence of disease.
Interventions
- BIOLOGICAL QS21
- BIOLOGICAL GM2-KLH vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 1998-01 |
| Est. Completion | 2001-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003357
The ClinicalTrials.gov registry entry for NCT00003357 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QS21 is the first listed.
NCT00003357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003357 about?
NCT00003357 is a clinical study titled "Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease". RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients with breast cancer who have no evidence of disease.
What is the current status of trial NCT00003357?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 1998-01. Estimated completion is 2001-11.
What interventions are being tested in trial NCT00003357?
The interventions under investigation include: QS21 (BIOLOGICAL), GM2-KLH vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003357?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.